RE:RE:RE:RE:Aduhelm stimulation btw, I assume you've looked at this week's conference presentation, so if you understood it you should be asking wtf is holding this back? Gene mentions Acumen, the financing there alone shows how ridiculously undervalued PMN is given the claimed advantages we have.
https://www.promisneurosciences.com/news-media/events/detail/8684/h-c-wainwright-bioconnect-2022-virtual-conference
So is it that the market doesn't believe in toxic misfolded proteins as root cause hypothesis, or doesn't know about the company, or doesn't trust the management?
I thought the presentation was impressive but we've seen all before so we know it will have no effect on the market. I commend Gene for finally getting past Aducanumab, almost, as it has been his security blanket for several years. But he still can't bring himself to criticize it in any way, even with the crooks at Biogen now flailing to squeeze some value out of it at the expense of Medicare (which the industry wants to bankrupt anyway).
And this brings up the competition going forward: Lily's Donanemab, Biogen/Esai's Lecanemab/Ban2401, and Acumen's ACU193:
Is Gene going to pander to his peers again, or is he going to say something bold that media can latch onto for his shareholders?
What would JFK say about before this decade is out...?